These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16504820)

  • 1. The pharmacoeconomics of newer therapeutics for rheumatic diseases.
    Kavanaugh A
    Rheum Dis Clin North Am; 2006 Feb; 32(1):45-56, viii. PubMed ID: 16504820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic issues with new rheumatologic therapeutics.
    Kavanaugh A
    Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of treatment in early rheumatoid arthritis.
    Bansback N; Marra CA; Finckh A; Anis A
    Best Pract Res Clin Rheumatol; 2009 Feb; 23(1):83-92. PubMed ID: 19233048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies.
    Lipsky PE; Kavanaugh A
    Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():41-4. PubMed ID: 10646490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness analysis of drug therapies for rheumatoid arthritis.
    Criswell LA; Such CL
    J Rheumatol Suppl; 1996 Mar; 44():52-5. PubMed ID: 8833053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economics: implications for novel antirheumatic therapies.
    Kavanaugh A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis: out of touch with clinical reality?
    Maetzel A
    Arthritis Rheum; 2005 Feb; 53(1):3-4. PubMed ID: 15696549
    [No Abstract]   [Full Text] [Related]  

  • 8. Rheumatoid arthritis.
    Sutor SM; Gricar JA; Cave DG
    Manag Care Interface; 1999 Jun; 12(6):51-3. PubMed ID: 10538460
    [No Abstract]   [Full Text] [Related]  

  • 9. Costs of rheumatoid arthritis in Hungary.
    Péntek M; Kobelt G; Czirják L; Szekanecz Z; Poór G; Rojkovich B; Polgár A; Genti G; Kiss CG; Brodszky V; Májer I; Gulácsi L
    J Rheumatol; 2007 Jun; 34(6):1437. PubMed ID: 17552071
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic consequences of established rheumatoid arthritis and its treatment.
    Kavanaugh A
    Best Pract Res Clin Rheumatol; 2007 Oct; 21(5):929-42. PubMed ID: 17870036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient access to rheumatoid arthritis treatments.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S33-4. PubMed ID: 18097698
    [No Abstract]   [Full Text] [Related]  

  • 12. Now that we know what's BeSt, what is good value for the money?
    Bansback N; Marra CA
    Arthritis Rheum; 2009 Mar; 61(3):289-90. PubMed ID: 19248126
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab (Rituxan) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?
    Yen JH
    Biomed Pharmacother; 2006 Dec; 60(10):688-92. PubMed ID: 17049202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modest proposal.
    Lipsky PE
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):343. PubMed ID: 16932714
    [No Abstract]   [Full Text] [Related]  

  • 16. [Solutions for off-label therapy].
    Schmidt WA
    Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al.
    Boers M
    Arthritis Rheum; 2009 Nov; 61(11):1616-7; author reply 1617-8. PubMed ID: 19877096
    [No Abstract]   [Full Text] [Related]  

  • 18. The rationale of pharmacoeconomic analysis in rheumatologic indications.
    Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bibliography. Current world literature. Clinical therapeutics.
    Curr Opin Rheumatol; 2007 May; 19(3):314-9. PubMed ID: 17414962
    [No Abstract]   [Full Text] [Related]  

  • 20. Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    van Vollenhoven RF;
    Rheumatology (Oxford); 2008 Jul; 47(7):1106-7; author reply 1107. PubMed ID: 18326533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.